dexmedetomidine

BioXCell’s potential episodic Alzheimer’s agitation treatment marred by missed trial protocols, fabricated emails and failed endpoint
Fierce Pharma
Thu, 06/29/23 - 11:42 am
BioXCell
Alzheimer's disease
Alzheimer's agitation
dexmedetomidine
SEC
BioXcel’s phase 3 schizophrenia film has blockbuster potential, say analysts
Pharmaforum
Fri, 09/4/20 - 10:11 am
BioXcel
schizophrenia
bipolar disorder
sublingual treatments
dexmedetomidine
clinical trials